Global Immune Checkpoint Inhibitors Market Insights, Forecast to 2028

Report ID: 1667127 | Published Date: Jan 2025 | No. of Page: 90 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Immune Checkpoint Inhibitors Product Introduction
    1.2 Market by Type
        1.2.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 PD-1/PD-L1
        1.2.3 CTLA-4
    1.3 Market by Application
        1.3.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Lung Cancer
        1.3.3 Colorectal Cancer
        1.3.4 Breast Cancer
        1.3.5 Prostate Cancer
        1.3.6 Melanoma
        1.3.7 Blood Cancer
        1.3.8 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Immune Checkpoint Inhibitors Sales Estimates and Forecasts 2017-2028
    2.2 Global Immune Checkpoint Inhibitors Revenue Estimates and Forecasts 2017-2028
    2.3 Global Immune Checkpoint Inhibitors Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Immune Checkpoint Inhibitors Sales by Region
        2.4.1 Global Immune Checkpoint Inhibitors Sales by Region (2017-2022)
        2.4.2 Global Sales Immune Checkpoint Inhibitors by Region (2023-2028)
    2.5 Global Immune Checkpoint Inhibitors Revenue by Region
        2.5.1 Global Immune Checkpoint Inhibitors Revenue by Region (2017-2022)
        2.5.2 Global Immune Checkpoint Inhibitors Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Immune Checkpoint Inhibitors Sales by Manufacturers
        3.1.1 Global Top Immune Checkpoint Inhibitors Manufacturers by Sales (2017-2022)
        3.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Immune Checkpoint Inhibitors in 2021
    3.2 Global Immune Checkpoint Inhibitors Revenue by Manufacturers
        3.2.1 Global Immune Checkpoint Inhibitors Revenue by Manufacturers (2017-2022)
        3.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Immune Checkpoint Inhibitors Revenue in 2021
    3.3 Global Immune Checkpoint Inhibitors Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Immune Checkpoint Inhibitors Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Immune Checkpoint Inhibitors Sales by Type
        4.1.1 Global Immune Checkpoint Inhibitors Historical Sales by Type (2017-2022)
        4.1.2 Global Immune Checkpoint Inhibitors Forecasted Sales by Type (2023-2028)
        4.1.3 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    4.2 Global Immune Checkpoint Inhibitors Revenue by Type
        4.2.1 Global Immune Checkpoint Inhibitors Historical Revenue by Type (2017-2022)
        4.2.2 Global Immune Checkpoint Inhibitors Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    4.3 Global Immune Checkpoint Inhibitors Price by Type
        4.3.1 Global Immune Checkpoint Inhibitors Price by Type (2017-2022)
        4.3.2 Global Immune Checkpoint Inhibitors Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Immune Checkpoint Inhibitors Sales by Application
        5.1.1 Global Immune Checkpoint Inhibitors Historical Sales by Application (2017-2022)
        5.1.2 Global Immune Checkpoint Inhibitors Forecasted Sales by Application (2023-2028)
        5.1.3 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    5.2 Global Immune Checkpoint Inhibitors Revenue by Application
        5.2.1 Global Immune Checkpoint Inhibitors Historical Revenue by Application (2017-2022)
        5.2.2 Global Immune Checkpoint Inhibitors Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    5.3 Global Immune Checkpoint Inhibitors Price by Application
        5.3.1 Global Immune Checkpoint Inhibitors Price by Application (2017-2022)
        5.3.2 Global Immune Checkpoint Inhibitors Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Immune Checkpoint Inhibitors Market Size by Type
        6.1.1 North America Immune Checkpoint Inhibitors Sales by Type (2017-2028)
        6.1.2 North America Immune Checkpoint Inhibitors Revenue by Type (2017-2028)
    6.2 North America Immune Checkpoint Inhibitors Market Size by Application
        6.2.1 North America Immune Checkpoint Inhibitors Sales by Application (2017-2028)
        6.2.2 North America Immune Checkpoint Inhibitors Revenue by Application (2017-2028)
    6.3 North America Immune Checkpoint Inhibitors Market Size by Country
        6.3.1 North America Immune Checkpoint Inhibitors Sales by Country (2017-2028)
        6.3.2 North America Immune Checkpoint Inhibitors Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Immune Checkpoint Inhibitors Market Size by Type
        7.1.1 Europe Immune Checkpoint Inhibitors Sales by Type (2017-2028)
        7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Type (2017-2028)
    7.2 Europe Immune Checkpoint Inhibitors Market Size by Application
        7.2.1 Europe Immune Checkpoint Inhibitors Sales by Application (2017-2028)
        7.2.2 Europe Immune Checkpoint Inhibitors Revenue by Application (2017-2028)
    7.3 Europe Immune Checkpoint Inhibitors Market Size by Country
        7.3.1 Europe Immune Checkpoint Inhibitors Sales by Country (2017-2028)
        7.3.2 Europe Immune Checkpoint Inhibitors Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Immune Checkpoint Inhibitors Market Size by Type
        8.1.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Type (2017-2028)
        8.1.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Type (2017-2028)
    8.2 Asia Pacific Immune Checkpoint Inhibitors Market Size by Application
        8.2.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Application (2017-2028)
        8.2.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Application (2017-2028)
    8.3 Asia Pacific Immune Checkpoint Inhibitors Market Size by Region
        8.3.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2017-2028)
        8.3.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Immune Checkpoint Inhibitors Market Size by Type
        9.1.1 Latin America Immune Checkpoint Inhibitors Sales by Type (2017-2028)
        9.1.2 Latin America Immune Checkpoint Inhibitors Revenue by Type (2017-2028)
    9.2 Latin America Immune Checkpoint Inhibitors Market Size by Application
        9.2.1 Latin America Immune Checkpoint Inhibitors Sales by Application (2017-2028)
        9.2.2 Latin America Immune Checkpoint Inhibitors Revenue by Application (2017-2028)
    9.3 Latin America Immune Checkpoint Inhibitors Market Size by Country
        9.3.1 Latin America Immune Checkpoint Inhibitors Sales by Country (2017-2028)
        9.3.2 Latin America Immune Checkpoint Inhibitors Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Type
        10.1.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Type (2017-2028)
    10.2 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Application
        10.2.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Application (2017-2028)
    10.3 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Country
        10.3.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Bristol Myer Squibb
        11.1.1 Bristol Myer Squibb Corporation Information
        11.1.2 Bristol Myer Squibb Overview
        11.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Bristol Myer Squibb Recent Developments
    11.2 AstraZeneca
        11.2.1 AstraZeneca Corporation Information
        11.2.2 AstraZeneca Overview
        11.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 AstraZeneca Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 AstraZeneca Recent Developments
    11.3 Merck
        11.3.1 Merck Corporation Information
        11.3.2 Merck Overview
        11.3.3 Merck Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Merck Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Merck Recent Developments
    11.4 Roche / Genentech
        11.4.1 Roche / Genentech Corporation Information
        11.4.2 Roche / Genentech Overview
        11.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Roche / Genentech Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Roche / Genentech Recent Developments
    11.5 Ono Pharmaceutical
        11.5.1 Ono Pharmaceutical Corporation Information
        11.5.2 Ono Pharmaceutical Overview
        11.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Ono Pharmaceutical Recent Developments
    11.6 Regeneron
        11.6.1 Regeneron Corporation Information
        11.6.2 Regeneron Overview
        11.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Regeneron Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Regeneron Recent Developments
    11.7 Innovent
        11.7.1 Innovent Corporation Information
        11.7.2 Innovent Overview
        11.7.3 Innovent Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Innovent Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Innovent Recent Developments
    11.8 Hengrui Medicine
        11.8.1 Hengrui Medicine Corporation Information
        11.8.2 Hengrui Medicine Overview
        11.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Hengrui Medicine Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Hengrui Medicine Recent Developments
    11.9 Junshi Biosciences
        11.9.1 Junshi Biosciences Corporation Information
        11.9.2 Junshi Biosciences Overview
        11.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Junshi Biosciences Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Junshi Biosciences Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Immune Checkpoint Inhibitors Industry Chain Analysis
    12.2 Immune Checkpoint Inhibitors Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Immune Checkpoint Inhibitors Production Mode & Process
    12.4 Immune Checkpoint Inhibitors Sales and Marketing
        12.4.1 Immune Checkpoint Inhibitors Sales Channels
        12.4.2 Immune Checkpoint Inhibitors Distributors
    12.5 Immune Checkpoint Inhibitors Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Immune Checkpoint Inhibitors Industry Trends
    13.2 Immune Checkpoint Inhibitors Market Drivers
    13.3 Immune Checkpoint Inhibitors Market Challenges
    13.4 Immune Checkpoint Inhibitors Market Restraints
14 Key Findings in The Global Immune Checkpoint Inhibitors Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of PD-1/PD-L1
    Table 3. Major Manufacturers of CTLA-4
    Table 4. Global Immune Checkpoint Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Immune Checkpoint Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Immune Checkpoint Inhibitors Sales by Region (2017-2022) & (MT)
    Table 7. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2017-2022)
    Table 8. Global Immune Checkpoint Inhibitors Sales by Region (2023-2028) & (MT)
    Table 9. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2023-2028)
    Table 10. Global Immune Checkpoint Inhibitors Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2017-2022)
    Table 12. Global Immune Checkpoint Inhibitors Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2023-2028)
    Table 14. Global Immune Checkpoint Inhibitors Sales by Manufacturers (2017-2022) & (MT)
    Table 15. Global Immune Checkpoint Inhibitors Sales Share by Manufacturers (2017-2022)
    Table 16. Global Immune Checkpoint Inhibitors Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2017-2022)
    Table 18. Immune Checkpoint Inhibitors Price by Manufacturers (2017-2022) &(USD/Kg)
    Table 19. Global Immune Checkpoint Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Immune Checkpoint Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2021)
    Table 21. Immune Checkpoint Inhibitors Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Immune Checkpoint Inhibitors Product Offered
    Table 23. Date of Manufacturers Enter into Immune Checkpoint Inhibitors Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Immune Checkpoint Inhibitors Sales by Type (2017-2022) & (MT)
    Table 26. Global Immune Checkpoint Inhibitors Sales by Type (2023-2028) & (MT)
    Table 27. Global Immune Checkpoint Inhibitors Sales Share by Type (2017-2022)
    Table 28. Global Immune Checkpoint Inhibitors Sales Share by Type (2023-2028)
    Table 29. Global Immune Checkpoint Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Immune Checkpoint Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Immune Checkpoint Inhibitors Revenue Share by Type (2017-2022)
    Table 32. Global Immune Checkpoint Inhibitors Revenue Share by Type (2023-2028)
    Table 33. Immune Checkpoint Inhibitors Price by Type (2017-2022) & (USD/Kg)
    Table 34. Global Immune Checkpoint Inhibitors Price Forecast by Type (2023-2028) & (USD/Kg)
    Table 35. Global Immune Checkpoint Inhibitors Sales by Application (2017-2022) & (MT)
    Table 36. Global Immune Checkpoint Inhibitors Sales by Application (2023-2028) & (MT)
    Table 37. Global Immune Checkpoint Inhibitors Sales Share by Application (2017-2022)
    Table 38. Global Immune Checkpoint Inhibitors Sales Share by Application (2023-2028)
    Table 39. Global Immune Checkpoint Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Immune Checkpoint Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Immune Checkpoint Inhibitors Revenue Share by Application (2017-2022)
    Table 42. Global Immune Checkpoint Inhibitors Revenue Share by Application (2023-2028)
    Table 43. Immune Checkpoint Inhibitors Price by Application (2017-2022) & (USD/Kg)
    Table 44. Global Immune Checkpoint Inhibitors Price Forecast by Application (2023-2028) & (USD/Kg)
    Table 45. North America Immune Checkpoint Inhibitors Sales by Type (2017-2022) & (MT)
    Table 46. North America Immune Checkpoint Inhibitors Sales by Type (2023-2028) & (MT)
    Table 47. North America Immune Checkpoint Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Immune Checkpoint Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Immune Checkpoint Inhibitors Sales by Application (2017-2022) & (MT)
    Table 50. North America Immune Checkpoint Inhibitors Sales by Application (2023-2028) & (MT)
    Table 51. North America Immune Checkpoint Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Immune Checkpoint Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Immune Checkpoint Inhibitors Sales by Country (2017-2022) & (MT)
    Table 54. North America Immune Checkpoint Inhibitors Sales by Country (2023-2028) & (MT)
    Table 55. North America Immune Checkpoint Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Immune Checkpoint Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Immune Checkpoint Inhibitors Sales by Type (2017-2022) & (MT)
    Table 58. Europe Immune Checkpoint Inhibitors Sales by Type (2023-2028) & (MT)
    Table 59. Europe Immune Checkpoint Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Immune Checkpoint Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Immune Checkpoint Inhibitors Sales by Application (2017-2022) & (MT)
    Table 62. Europe Immune Checkpoint Inhibitors Sales by Application (2023-2028) & (MT)
    Table 63. Europe Immune Checkpoint Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Immune Checkpoint Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Immune Checkpoint Inhibitors Sales by Country (2017-2022) & (MT)
    Table 66. Europe Immune Checkpoint Inhibitors Sales by Country (2023-2028) & (MT)
    Table 67. Europe Immune Checkpoint Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Immune Checkpoint Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Immune Checkpoint Inhibitors Sales by Type (2017-2022) & (MT)
    Table 70. Asia Pacific Immune Checkpoint Inhibitors Sales by Type (2023-2028) & (MT)
    Table 71. Asia Pacific Immune Checkpoint Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Immune Checkpoint Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Immune Checkpoint Inhibitors Sales by Application (2017-2022) & (MT)
    Table 74. Asia Pacific Immune Checkpoint Inhibitors Sales by Application (2023-2028) & (MT)
    Table 75. Asia Pacific Immune Checkpoint Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Immune Checkpoint Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2017-2022) & (MT)
    Table 78. Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2023-2028) & (MT)
    Table 79. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Immune Checkpoint Inhibitors Sales by Type (2017-2022) & (MT)
    Table 82. Latin America Immune Checkpoint Inhibitors Sales by Type (2023-2028) & (MT)
    Table 83. Latin America Immune Checkpoint Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Immune Checkpoint Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Immune Checkpoint Inhibitors Sales by Application (2017-2022) & (MT)
    Table 86. Latin America Immune Checkpoint Inhibitors Sales by Application (2023-2028) & (MT)
    Table 87. Latin America Immune Checkpoint Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Immune Checkpoint Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Immune Checkpoint Inhibitors Sales by Country (2017-2022) & (MT)
    Table 90. Latin America Immune Checkpoint Inhibitors Sales by Country (2023-2028) & (MT)
    Table 91. Latin America Immune Checkpoint Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Immune Checkpoint Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Immune Checkpoint Inhibitors Sales by Type (2017-2022) & (MT)
    Table 94. Middle East and Africa Immune Checkpoint Inhibitors Sales by Type (2023-2028) & (MT)
    Table 95. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2017-2022) & (MT)
    Table 98. Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2023-2028) & (MT)
    Table 99. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2017-2022) & (MT)
    Table 102. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2023-2028) & (MT)
    Table 103. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 105. Bristol Myer Squibb Corporation Information
    Table 106. Bristol Myer Squibb Description and Major Businesses
    Table 107. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 108. Bristol Myer Squibb Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. Bristol Myer Squibb Recent Developments
    Table 110. AstraZeneca Corporation Information
    Table 111. AstraZeneca Description and Major Businesses
    Table 112. AstraZeneca Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 113. AstraZeneca Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. AstraZeneca Recent Developments
    Table 115. Merck Corporation Information
    Table 116. Merck Description and Major Businesses
    Table 117. Merck Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 118. Merck Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Merck Recent Developments
    Table 120. Roche / Genentech Corporation Information
    Table 121. Roche / Genentech Description and Major Businesses
    Table 122. Roche / Genentech Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 123. Roche / Genentech Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Roche / Genentech Recent Developments
    Table 125. Ono Pharmaceutical Corporation Information
    Table 126. Ono Pharmaceutical Description and Major Businesses
    Table 127. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 128. Ono Pharmaceutical Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Ono Pharmaceutical Recent Developments
    Table 130. Regeneron Corporation Information
    Table 131. Regeneron Description and Major Businesses
    Table 132. Regeneron Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 133. Regeneron Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Regeneron Recent Developments
    Table 135. Innovent Corporation Information
    Table 136. Innovent Description and Major Businesses
    Table 137. Innovent Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 138. Innovent Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Innovent Recent Developments
    Table 140. Hengrui Medicine Corporation Information
    Table 141. Hengrui Medicine Description and Major Businesses
    Table 142. Hengrui Medicine Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 143. Hengrui Medicine Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Hengrui Medicine Recent Developments
    Table 145. Junshi Biosciences Corporation Information
    Table 146. Junshi Biosciences Description and Major Businesses
    Table 147. Junshi Biosciences Immune Checkpoint Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 148. Junshi Biosciences Immune Checkpoint Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Junshi Biosciences Recent Developments
    Table 150. Key Raw Materials Lists
    Table 151. Raw Materials Key Suppliers Lists
    Table 152. Immune Checkpoint Inhibitors Distributors List
    Table 153. Immune Checkpoint Inhibitors Customers List
    Table 154. Immune Checkpoint Inhibitors Market Trends
    Table 155. Immune Checkpoint Inhibitors Market Drivers
    Table 156. Immune Checkpoint Inhibitors Market Challenges
    Table 157. Immune Checkpoint Inhibitors Market Restraints
    Table 158. Research Programs/Design for This Report
    Table 159. Key Data Information from Secondary Sources
    Table 160. Key Data Information from Primary Sources
List of Figures
    Figure 1. Immune Checkpoint Inhibitors Product Picture
    Figure 3. Global Immune Checkpoint Inhibitors Market Share by Type in 2021 & 2028
    Figure 3. PD-1/PD-L1 Product Picture
    Figure 4. CTLA-4 Product Picture
    Figure 5. Global Immune Checkpoint Inhibitors Market Share by Application in 2021 & 2028
    Figure 6. Lung Cancer
    Figure 7. Colorectal Cancer
    Figure 8. Breast Cancer
    Figure 9. Prostate Cancer
    Figure 10. Melanoma
    Figure 11. Blood Cancer
    Figure 12. Other
    Figure 13. Immune Checkpoint Inhibitors Report Years Considered
    Figure 14. Global Immune Checkpoint Inhibitors Sales 2017-2028 (MT)
    Figure 15. Global Immune Checkpoint Inhibitors Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Immune Checkpoint Inhibitors Revenue 2017-2028 (US$ Million)
    Figure 17. Global Immune Checkpoint Inhibitors Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 18. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2017-2022)
    Figure 19. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2023-2028)
    Figure 20. North America Immune Checkpoint Inhibitors Sales YoY (2017-2028) & (MT)
    Figure 21. North America Immune Checkpoint Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Immune Checkpoint Inhibitors Sales YoY (2017-2028) & (MT)
    Figure 23. Europe Immune Checkpoint Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Asia-Pacific Immune Checkpoint Inhibitors Sales YoY (2017-2028) & (MT)
    Figure 25. Asia-Pacific Immune Checkpoint Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Latin America Immune Checkpoint Inhibitors Sales YoY (2017-2028) & (MT)
    Figure 27. Latin America Immune Checkpoint Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Middle East & Africa Immune Checkpoint Inhibitors Sales YoY (2017-2028) & (MT)
    Figure 29. Middle East & Africa Immune Checkpoint Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. The Immune Checkpoint Inhibitors Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 31. The Top 5 and 10 Largest Manufacturers of Immune Checkpoint Inhibitors in the World: Market Share by Immune Checkpoint Inhibitors Revenue in 2021
    Figure 32. Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 33. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    Figure 34. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 35. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    Figure 36. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 37. North America Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    Figure 38. North America Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 39. North America Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    Figure 40. North America Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 41. North America Immune Checkpoint Inhibitors Sales Share by Country (2017-2028)
    Figure 42. North America Immune Checkpoint Inhibitors Revenue Share by Country (2017-2028)
    Figure 43. U.S. Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 44. Canada Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 45. Europe Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    Figure 46. Europe Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 47. Europe Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    Figure 48. Europe Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 49. Europe Immune Checkpoint Inhibitors Sales Share by Country (2017-2028)
    Figure 50. Europe Immune Checkpoint Inhibitors Revenue Share by Country (2017-2028)
    Figure 51. Germany Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 52. France Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 53. U.K. Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 54. Italy Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 55. Russia Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 56. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Immune Checkpoint Inhibitors Sales Share by Region (2017-2028)
    Figure 61. Asia Pacific Immune Checkpoint Inhibitors Revenue Share by Region (2017-2028)
    Figure 62. China Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 63. Japan Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 64. South Korea Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 65. India Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 66. Australia Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 67. Taiwan Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 68. Indonesia Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 69. Thailand Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 70. Malaysia Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 71. Philippines Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 72. Latin America Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    Figure 73. Latin America Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 74. Latin America Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    Figure 75. Latin America Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 76. Latin America Immune Checkpoint Inhibitors Sales Share by Country (2017-2028)
    Figure 77. Latin America Immune Checkpoint Inhibitors Revenue Share by Country (2017-2028)
    Figure 78. Mexico Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 79. Brazil Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 80. Argentina Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 81. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa Immune Checkpoint Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa Immune Checkpoint Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Immune Checkpoint Inhibitors Sales Share by Country (2017-2028)
    Figure 86. Middle East and Africa Immune Checkpoint Inhibitors Revenue Share by Country (2017-2028)
    Figure 87. Turkey Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 88. Saudi Arabia Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 89. U.A.E Immune Checkpoint Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 90. Immune Checkpoint Inhibitors Value Chain
    Figure 91. Immune Checkpoint Inhibitors Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Frequently Asked Questions
Immune Checkpoint Inhibitors report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Immune Checkpoint Inhibitors report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Immune Checkpoint Inhibitors report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Immunoglobulins

Immunoglobulins market is segmented by Type and by Application. Players, stakeholders, and other  ... Read More

Immunology Drug

Immunology Drug market is segmented by Type and by Application. Players, stakeholders, and other  ... Read More